Los Altos, Calif.-based RonovoRx has received a new 510(k) clearance from the FDA for its RenovoCath delivery system, a dual-balloon infusion catheter that delivers chemotherapy directly to solid tumors via arteries.

RenovoRx received its initial 510(k) clearance for the RenovoCath delivery system in 2014. The redesigned catheter provides more targeted delivery of therapy which can translate into more effective treatment with fewer side effects, the company said.

RenovoCath is part of the company's micro-perfusion therapy platform, RenovoTAMP, which is being studied for its potential to enable physicians to isolate the anatomy and micro-perfuse targeted tissue with small-molecule chemotherapy.